Accredo Specialty Pharmacy | Accredo Patient Support

We are committed to making CARBAGLU affordable and accessible.

zero co-pay

Recordati Rare Diseases, the distributor of CARBAGLU® (carglumic acid) tablets for oral suspension 200mg, is offering a $0 copay for qualified patients with commercial insurance. CARBAGLU has a proven track record of quality, safety, and efficacy, as well as personalized patient support programs for people taking CARBAGLU. Although we do not replace the advice of your doctor, we can help you with your questions. We have you covered!

1-888-454-8860 (toll-free)

Recordati Rare Diseases Patient Support Program

The Recordati Rare Diseases Patient Support Program includes:

  • Co-Pay Support Program

    Get help with Insurance co-pay and co-insurance costs. Find out if you qualify for a $0 co-pay for CARBAGLU.

  • Insurance Verification

    Get help with confirming that your insurance company will cover CARBAGLU, and get help in understanding your insurance plan benefits.

  • Prior Authorization Support

    Get help working with your doctor’s office and insurance company if additional approvals are needed.

  • Patient Liaison (PL)

    Personalized one-on-one support for eligible NAGS deficiency patients and their caregivers*

    * Information provided by the PL program is for educational purposes only and is not intended to replace the advice of patients’ healthcare providers.
    COMPLETE THE OPT-IN FORM

  • Alternate Funding Referrals

    Get help in researching alternative forms of medication coverage, or get referrals to other possible sources of funding.

  • Patient Assistance Program

    Get assistance with accessing medications if you don’t have insurance or are underinsured.*

    *Eligibility requirements may apply.

Where can I get more support?

For more information about NAGS deficiency, PA, and MMA, check out these resources:

  • Organic Acidemia Association - logo

    The mission of the Organic Acidemia Association is to find improved treatments and a cure for propionic acidemia (PA) and methylmalonic acidemia (MMA) by funding research and providing information and support to families and medical professionals. Services and programs for families include educational materials, family matching to enable families to talk to each other, and an email group.

  • Propionic Acidemia Foundation - logo

    The mission of the Propionic Acidemia Foundation is to find improved treatments and a cure for propionic acidemia (PA) by funding research and providing information and support to families and medical professionals. Services and programs for families include educational materials, family matching to enable families to talk to each other, and an email group.

  • National Urea Cycle Disorders Foundation (NUCDF) - logo

    The National Urea Cycle Disorders Foundation (NUCDF) is dedicated to the identification, treatment, and cure of urea cycle disorders. NUCDF provides information and education for families and doctors. NUCDF offers two support programs for families: a mentor program, which matches newly diagnosed families with a mentor from the UCD community; and a networking program, which enables UCD patients and families to communicate with each other.

  • Genetic and Rare Diseases Information Center (GARD) - logo

    Genetic and Rare Diseases Information Center (GARD) of the National Institutes of Health provides information for individuals with genetic and rare diseases, their families, and others.

  • National Organization for Rare Disorders (NORD) - logo

    The National Organization for Rare Disorders (NORD) is dedicated to helping people with rare diseases. NORD provides information and resources for families, as well as ways to connect with others and get involved in the rare diseases community.

  • Rare Diseases Clinical Research Network | National Insititute of Health - logo

    The Urea Cycle Disorders Consortium, part of the Rare Diseases Clinical Research Network founded by the National Institutes of Health, is a team of doctors, nurses, and researchers working together to improve the lives of people with urea cycle disorders through research and education. The purpose of the consortium is to provide ways for patients to join with doctors and researchers through participation in research studies.

INDICATION(S) AND IMPORTANT SAFETY INFORMATION

What is CARBAGLU?

Carbaglu® (carglumic acid) tablets for oral suspension 200 mg is a prescription medicine used in adults and children to:

  • supplement standard of care treatment for acute high blood ammonia levels (hyperammonemia) due to the lack or shortage of NAGS enzyme activity.
  • maintain normal blood ammonia levels due to the lack or shortage of NAGS enzyme activity.
  • supplement standard of care treatment for acute high blood ammonia levels (hyperammonemia) due to propionic acidemia (PA) or methylmalonic acidemia (MMA).

IMPORTANT SAFETY INFORMATION

Before starting CARBAGLU, tell your healthcare provider (HCP) about all your medical conditions, including if you are pregnant or plan to become pregnant, breastfeeding or plan to breastfeed. Tell your HCP about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements.

Tell your healthcare provider if you are pregnant. Women with NAGS deficiency who are exposed to CARBAGLU during pregnancy can participate in a pregnancy surveillance program that monitors pregnancy outcomes.

What are the possible side effects of CARBAGLU?

The most common side effects of CARBAGLU in studies for NAGS deficiency (in ≥13% of patients) are: vomiting, abdominal pain, fever, inflammation of the tonsils, reduced red cells in the blood, diarrhea, ear infection, infections, inflammation of the throat and nasal passages, hemoglobin decreased in red blood cells, and headache.

The most common side effects of CARBAGLU in studies for PA and MMA (in ≥5% of patients) are: lower than normal white blood cells, reduced red cells in the blood, vomiting, abnormal levels of minerals in the body, decreased appetite, low blood sugar levels, lack of energy/unresponsiveness, brain disease that alters brain structure or function, and inflammation of the pancreas / increase in a type of protein made by the pancreas that helps the body digest fats.

These are not all the possible side effects of CARBAGLU. Call your healthcare provider for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Call FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

CARBAGLU® (carglumic acid) is available as 200 mg tablets for oral suspension.

Please see the accompanying full Prescribing Information, including Instructions for Use.

See LessSee More
X
X
X
X
X
X

You are about to leave the CARBAGLU.com website and enter a website operated by an independent third party. The links to third-party websites contained on CARBAGLU.com are provided solely for your convenience. Recordati Rare Diseases does not control the opinions, claims or comments contained on any third-party website linked to CARBAGLU.com, and your activities at those websites will be governed by the policies and practices of those third parties.

OK to proceed to third-party website CANCEL to return to CARBAGLU.com